Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020
May 07, 2020 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock
May 06, 2020 09:00 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Announces Commencement of Public Offering of Common Stock
May 05, 2020 16:01 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 05, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports First Quarter 2020 Financial Results
May 04, 2020 16:05 ET
|
Kura Oncology, Inc.
– Enhanced focus on tipifarnib in HRAS mutant HNSCC and KO-539 menin inhibitor in NPM1-mutant and KMT2A(MLL)-rearranged AML – – Three abstracts accepted for presentation at ASCO, including mature...
Kura Oncology to Report First Quarter 2020 Financial Results
April 29, 2020 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, April 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 23, 2019 16:05 ET
|
Kura Oncology, Inc.
– Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29th – – Previously announced poster...
Kura Oncology Expands Board of Directors with Appointment of Diane Parks
October 15, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia
September 16, 2019 07:30 ET
|
Kura Oncology, Inc.
– KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction – – First-in-human trial to determine MTD, expand to genetic subgroups such as NPM1 – SAN DIEGO, Sept. 16, 2019 ...
Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer
August 12, 2019 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology to Present at Wedbush PacGrow Healthcare Conference
August 07, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...